Clinical Trials
25 trialsNCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT07343960 2026-05-20
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
Phase 1 Recruiting
NCT07287917 2026-05-12
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Aminex Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06982521 2026-05-08
ReDiscover-2
Relay Therapeutics, Inc.
Phase 3 Recruiting
NCT04493853 2026-05-05
CAPItello-281
AstraZeneca
Phase 3 Active not recruiting
NCT03616587 2026-04-30
SERENA-1
AstraZeneca
Phase 1 Active not recruiting
NCT04305496 2026-04-30
CAPItello-291
AstraZeneca
Phase 3 Active not recruiting
NCT03742102 2026-04-24
BEGONIA
AstraZeneca
Phase 1/2 Active not recruiting
NCT07241065 2026-04-15
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
AstraZeneca
Phase 1 Recruiting
NCT06764186 2026-04-08
CAPItana
AstraZeneca
Phase 3 Active not recruiting
NCT06635447 2026-03-27
CAPItrue
AstraZeneca
Phase 3 Active not recruiting
NCT07088913 2026-03-03
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03997123 2025-12-22
CAPItello-290
AstraZeneca
Phase 3 Active not recruiting
NCT04556773 2025-12-17
DB-08
AstraZeneca
Phase 1 Active not recruiting
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT05348577 2025-01-27
CAPItello280
AstraZeneca
Phase 3 Active not recruiting
NCT05008055 2024-12-20
CAPITAL
AstraZeneca
Phase 2 Completed
NCT04958226 2024-01-25
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT04742036 2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1 Completed
NCT04087174 2022-07-13
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
AstraZeneca
Phase 1 Completed
NCT04944771 2022-05-09
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
AstraZeneca
Phase 1 Completed
NCT04712396 2021-04-09
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
AstraZeneca
Phase 1 Completed
NCT01895946 2016-05-25
OAK
AstraZeneca
Phase 1 Completed
NCT01353781 2016-04-26
Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed